Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

new zealand medical & scientific ltd - vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml vinorelbine - solution for injection - 10 mg/ml - active: vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml vinorelbine excipient: water for injection

Malta - angleščina - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - vinorelbine tartrate - concentrate for solution for infusion - vinorelbine tartrate 13.85 mg - antineoplastic agents

Malta - angleščina - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - vinorelbine tartrate - concentrate for solution for infusion - vinorelbine tartrate 10 mg/ml - antineoplastic agents

Malta - angleščina - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - vinorelbine tartrate - concentrate for solution for infusion - vinorelbine tartrate 10 mg/ml - antineoplastic agents

Malta - angleščina - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - vinorelbine tartrate - concentrate for solution for infusion - vinorelbine tartrate 10 mg/ml - antineoplastic agents

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

new zealand medical & scientific ltd - vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml vinorelbine - solution for injection - 10 mg/ml - active: vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml vinorelbine excipient: water for injection

Irska - angleščina - HPRA (Health Products Regulatory Authority)

cardinal health uk 434 limited - vinorelbine tartrate - concentrate for soln for inf - 10 mg/ml

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: gelatin; partially dehydrated liquid sorbitol; polysorbate 80; macrogol 400; titanium dioxide; purified water; iron oxide red - non-small cell lung cancer: velabine is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: velabine is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: purified water; polysorbate 80; iron oxide yellow; gelatin; titanium dioxide; macrogol 400; partially dehydrated liquid sorbitol - non-small cell lung cancer: velabine is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: velabine is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: iron oxide yellow; macrogol 400; polysorbate 80; gelatin; purified water; titanium dioxide; partially dehydrated liquid sorbitol - non-small cell lung cancer: velabine is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: velabine is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.